Redhill Biopharma Ltd. (NASDAQ:RDHL) announced its earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.02, Morningstar.com reports. The firm had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.34 million.
Redhill Biopharma (NASDAQ:RDHL) traded up 2.03% during trading on Friday, reaching $9.03. The company had a trading volume of 55,398 shares. The firm’s 50 day moving average price is $9.06 and its 200 day moving average price is $9.64. Redhill Biopharma has a 12-month low of $8.16 and a 12-month high of $16.36. The firm’s market capitalization is $154.98 million.
A number of institutional investors have recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Redhill Biopharma during the fourth quarter worth about $4,087,000. Renaissance Technologies LLC purchased a new position in shares of Redhill Biopharma during the fourth quarter worth about $266,000. Family Management Corp purchased a new position in shares of Redhill Biopharma during the first quarter worth about $163,000. Oppenheimer & Co. Inc. boosted its position in shares of Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after buying an additional 6,172 shares during the last quarter. Finally, Penserra Capital Management LLC boosted its position in shares of Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock worth $171,000 after buying an additional 7,647 shares during the last quarter. 12.31% of the stock is owned by institutional investors and hedge funds.
Several brokerages have recently commented on RDHL. HC Wainwright set a $33.00 target price on Redhill Biopharma and gave the stock a “buy” rating in a report on Wednesday, July 26th. Roth Capital set a $27.00 price target on Redhill Biopharma and gave the company a “buy” rating in a report on Monday, July 31st. Zacks Investment Research cut Redhill Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, July 29th. Finally, FBR & Co reiterated a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th.
COPYRIGHT VIOLATION NOTICE: This news story was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/06/redhill-biopharma-ltd-rdhl-releases-earnings-results-misses-estimates-by-0-02-eps-updated.html.
About Redhill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
